
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 5, 2017

Dextera Surgical Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

000-51772
(Commission
File Number)

94-3287832
(IRS Employer
Identification No.)

900 Saginaw Drive, Redwood City, CA
(Address of Principal Executive Offices)

94063
(Zip Code)

Registrant's telephone number, including area code: (650) 364-9975

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition

On October 5, 2017, Dexter Surgical Inc. issued a corporate update for its fiscal quarter ended September 30, 2017. A copy of Dexter's press release, dated October 5, 2017, is attached hereto as Exhibit 99.1.

The information set forth under this Item 2.02, including the exhibit attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.**Exhibit No. Description**

99.1 Press release dated October 5, 2017, containing Dexter Surgical Inc.'s corporate update for the fiscal quarter ended September 30, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dextera Surgical Inc.
(Registrant)

Date: October 5, 2017

/s/ Robert Y. Newell

Robert Y. Newell, Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	<u>Press release dated October 5, 2017, containing Dextera Surgical Inc.'s corporate update for the fiscal quarter ended September 30, 2017.</u>



DEXTERA SURGICAL PROVIDES CORPORATE UPDATE

– Preliminary Fiscal 2018 First Quarter Revenue –

– Update on Strategic Partnership –

– Conference Call at 8:30 a.m. ET Today –

REDWOOD CITY, Calif. – October 5, 2017 – Dextera Surgical Inc. (Nasdaq: DXTR), a company developing and commercializing the MicroCutter 5/80™ Stapler, today announced that revenue for the third quarter of fiscal 2018 will be approximately \$568,000, with a current backorder of approximately \$178,000 for MicroCutter Staplers and reloads.

“As we have scaled up production of the MicroCutter 5/80, we have had difficulty qualifying some of the raw material for our reloads and as a result we experienced limited ability to ship product to our customers,” said Julian Nikolchev, president and CEO of Dextera Surgical. “We are working diligently to resolve these issues.”

Mr. Nikolchev continued, “While we continue to have active discussions with B. Braun regarding a strategic collaboration, these discussions are taking longer than expected and with support from our investment banker, the Board has decided to explore all strategic options available to us at this time.”

Conference Call Details

To access the live conference call today at 8:30 a.m. Eastern Time via phone, please dial 844-419-1785 from the United States and Canada or 216-562-0472. The conference ID is 96063203. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately four hours after the call through October 12, 2017, and may be accessed by dialing 855-859-2056 from the United States and Canada or 404-537-3406 internationally. The replay passcode is 96063203.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company’s website at ir.dexterasurgical.com. Please connect to the website at least 15 minutes prior to the presentation to allow for any necessary software downloads.

The webcast is also being distributed through the Thomson StreetEvents Network. Institutional investors can access the call via Thomson StreetEvents at www.streetevents.com, a password-protected event management site.

About Dextera Surgical

Dextera Surgical designs and manufactures proprietary stapling devices for minimally invasive surgical procedures. In the U.S., surgical staplers are routinely used in more than one million minimally invasive laparoscopic, video-assisted or robotic-assisted surgical procedures annually.

Dextera Surgical also markets the only automated anastomosis devices for coronary artery bypass graft (CABG) surgery on the market today: the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System. These products, sold by Dextera Surgical under the Cardica brand name, have demonstrated long-term reliable clinical performance for more than a decade.

###

Forward-Looking Statements

The statements in this press release regarding the expected revenue for the first quarter of fiscal year 2018 are "forward-looking statements." There are a number of important factors that could cause results to differ materially from those indicated by these forward-looking statements, including that the company has not closed its books for the quarter and unexpected changes may be discovered during the closing process. Other risks regarding Dextera Surgical are detailed from time to time in Dextera Surgical's reports filed with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, under the caption "Risk Factors." Dextera Surgical expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Dextera Surgical's reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.

Contact:

Bob Newell
Vice President, Finance and Chief Financial Officer
(650) 331-7133
investors@dexterasurgical.com